<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317183</url>
  </required_header>
  <id_info>
    <org_study_id>00010556-IORG 0008839</org_study_id>
    <nct_id>NCT04317183</nct_id>
  </id_info>
  <brief_title>Topical Chamomile in Preventing Chemotherapy-induced Oral Mucositis</brief_title>
  <official_title>The Effect of Topical Chamomile in the Prevention of Chemotherapy-induced Oral Mucositis (a Randomized Controlled Clinical Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hams Hamed Abdelrahman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the main aim of this study is to clinically assess the effectiveness of topical chamomile
      oral gel in the prevention of chemotherapy-induced oral mucositis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed as a randomized, controlled, clinical trial. patients who were
      undergoing to receive chemotherapy were divided into three groups: Group I: was given
      conventional treatment. Group II: was given topical oral gel of chamomile. Group III: was
      given topical oral gel of chamomile in combination with the conventional treatment.

      All patients have clinically evaluated at the start of the chemotherapy and three weeks later
      for pain and oral mucositis severity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in severity of oral mucositis at different time points along the study</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Oral mucositis will be evaluated by the World Health Organization (WHO) scale which record the extent and severity of oral mucositis at the third week after the first chemotherapy session.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain and discomfort severity at different time points along the study: Numeric Rating Scale</measure>
    <time_frame>Up to 3 weeks</time_frame>
    <description>Discomfort and pain severity were reported by each patient using Numeric Rating Scale (NRS) at the first , second and third week after the chemotherapy session.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Oral Mucositis Due to Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Chamomile topical gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical oral chamomile gel three times daily for three weeks.
Topical oral chamomile gel is prepared with the aid of Pharmacognosy and pharmaceutics departments, faculty of pharmacy, Alexandria University and mucoadhesive hydrogels (Carbopol® 970).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional therapy (symptomatic treatment) which included:
Miconaz oral gel BBC oral spray Oracure gel
Dose: Three times a day for three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical oral chamomile gel three times daily for three weeks in combination with the symptomatic treatment
Symptomatic treatment which included:
Miconaz oral gel BBC oral spray Oracure gel
Symptomatic treatment dose: Three times a day for three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chamomile topical oral gel</intervention_name>
    <description>Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.</description>
    <arm_group_label>Chamomile topical gel</arm_group_label>
    <arm_group_label>combination therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miconazole Topical Gel</intervention_name>
    <description>topical anti fungal agent</description>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_label>conventional therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBC oral spray</intervention_name>
    <description>Topical anesthetics and anti-inflammatory agent</description>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_label>conventional therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oracure gel</intervention_name>
    <description>Topical analgesic gel</description>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_label>conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are going to receive 5-Fluoroucil (5-FU) based chemotherapy regime.

        Males and females with an age of not less than 20 years and not exceeding 70 years.

        Exclusion Criteria:

          -  1. Patients suffering from any uncontrolled systemic diseases that affect integrity of
             the epithelium (such as diabetes, cardiovascular, liver disorder and renal
             dysfunction) 2. Pregnant and lactating women 3. Patients with findings of any physical
             or mental abnormality which would interfere with or be affected by the study procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehsan El-Negomy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maha Talaab, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reham Ibrahim, Phd</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasha El-Saka</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Elhadad, BDS</last_name>
    <phone>01009394469</phone>
    <email>elhadad2008@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Outpatient clinic of Department of Clinical Oncology, Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Elhadad</last_name>
      <phone>01009394469</phone>
      <email>elhadad2008@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Presibella MM, Villas-Bôas LDB, Belletti KMdS, Santos CAdM, Weffort-Santos AM. Comparison of chemical constituents of Chamomilla recutita (L.) Rauschert essential oil and its anti-chemotactic activity. Brazilian archives of biology and technology. 2006;49(5):717-24.</citation>
  </reference>
  <reference>
    <citation>Ferreira E, Vasques C, Jesus C, Reis P. Topical effects of Chamomilla recutita in skin damage: a literature review. 2015.</citation>
  </reference>
  <reference>
    <citation>Tadbir AA, Pourshahidi S, Ebrahimi H, Hajipour Z, Memarzade MR, Shirazian SJJoHM. The effect of Matricaria chamomilla (chamomile) extract in Orabase on minor aphthous stomatitis, a randomized clinical trial. 2015;5(2):71-6.</citation>
  </reference>
  <reference>
    <citation>Fidler P, Loprinzi CL, O'Fallon JR, Leitch JM, Lee JK, Hayes DL, Novotny P, Clemens-Schutjer D, Bartel J, Michalak JC. Prospective evaluation of a chamomile mouthwash for prevention of 5-FU-induced oral mucositis. Cancer. 1996 Feb 1;77(3):522-5.</citation>
    <PMID>8630960</PMID>
  </reference>
  <reference>
    <citation>Braga FT, Santos AC, Bueno PC, Silveira RC, Santos CB, Bastos JK, Carvalho EC. Use of Chamomilla recutita in the Prevention and Treatment of Oral Mucositis in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Randomized, Controlled, Phase II Clinical Trial. Cancer Nurs. 2015 Jul-Aug;38(4):322-9. doi: 10.1097/NCC.0000000000000194.</citation>
    <PMID>25232958</PMID>
  </reference>
  <reference>
    <citation>Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. J Natl Med Assoc. 2005 Aug;97(8):1161-4.</citation>
    <PMID>16173332</PMID>
  </reference>
  <reference>
    <citation>Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004 May 1;100(9 Suppl):1995-2025. Review.</citation>
    <PMID>15108222</PMID>
  </reference>
  <reference>
    <citation>Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, Elting LS, Fox PC, Cooksley C, Sonis ST; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004 May 1;100(9 Suppl):2026-46.</citation>
    <PMID>15108223</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Hams Hamed Abdelrahman</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>oral mucositis, chemotherapy, chamomile.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

